Form 4: Corcept Therapeutics Officer Reports Stock Transactions

Sean Maduck, President of Corcept Endocrinology, reports stock transactions including tax withholding, purchase plan acquisitions, and holdings in related entities.

Summary

• On March 1, 2024, Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics, engaged in several transactions involving the company's common stock.
• 505 shares were withheld by the issuer to cover tax obligations related to vesting restricted stock units at a price of $24.06.
• Maduck purchased 636 shares under the company's purchase plan at $24.06 per share.
• Additionally, 636 shares were acquired under unvested restricted stock awards granted through the purchase plan.
• Maduck directly owns 75,222 shares, which includes unvested restricted stock awards.
• He also indirectly owns 10,000 shares through Duckhill Capital, LLC and another 10,000 shares through the Sean and Molly Maduck Living Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing of stock transactions. The officer's participation in the purchase plan is mildly positive, but the tax withholding is a neutral event.

Positives

• The officer's participation in the company's purchase plan demonstrates confidence in the company's future.
• The increase in direct share ownership, even with tax withholding, suggests a positive outlook.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their trading activities. These filings are closely watched by investors seeking insights into management's perspective on the company's prospects.

Stakeholder Impact

• Shareholders may be interested in the insider's transactions as an indicator of management's confidence.
• The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates